BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 43 resultados LastUpdate Última actualización 02/04/2020 [18:43:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 2 nextPage   por página


SCREENING METHOD

NºPublicación: EP3627152A1 25/03/2020

Solicitante:

TAKEDA PHARMACEUTICALS CO [JP]

JP_WO2018212312_A1

Resumen de: EP3627152A1

The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.

traducir

TRANSGENIC INVERTEBRATE MODEL OF ALZHEIMER'S DISEASE AND UTILIZATION THEREOF

NºPublicación: EP3626074A1 25/03/2020

Solicitante:

NAT CENTER FOR GERIATRICS AND GERONTOLOGY [JP]

CN_110678070_A

Resumen de: EP3626074A1

The present invention provides a transgenic invertebrate model for Alzheimer's disease and a method for screening a therapeutic agent for Alzheimer's disease using the model. The present invention provides a transgenic invertebrate, in which genes encoding enzymes involved in production of a ganglioside are introduced and the ganglioside is expressed.

traducir

SYSTEMS

NºPublicación: US2020087665A1 19/03/2020

Solicitante:

NEW YORK STEM CELL FOUND INC [US]

CA_3062995_A1

Resumen de: US2020087665A1

An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.

traducir

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU

NºPublicación: US2020087387A1 19/03/2020

Solicitante:

OLIGOMERIX INC [US]

US_2018298086_A1

Resumen de: US2020087387A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomelic tau, fibrillar tau or non-disease associated forms of tau.

traducir

METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación: US2020088724A1 19/03/2020

Solicitante:

UNIV CALIFORNIA [US]

WO_2018081085_PA

Resumen de: US2020088724A1

Provided are methods of mitigating, reversing or eliminating in a subject one or more symptoms associated with cognitive impairment associated with amyloid deposits in the brain (e.g., olfactory dysfunction as a risk factor of dementia, mild cognitive impairment, Alzheimer's Disease) by detecting and targeting gram negative bacteria in the brain.

traducir

METHOD FOR DIAGNOSING DEMENTIA OR DETERMINING THE RISK OF DEVELOPING DEMENTIA

NºPublicación: WO2020053556A1 19/03/2020

Solicitante:

UNIV NEWCASTLE [GB]

Resumen de: WO2020053556A1

The present invention provides novel biomarkers for dementia. Methods for diagnosing dementia or the risk of developing dementia, or for monitoring dementia progression are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens or determining a subject's compliance or adherence with a prescribed treatment regimen. A method for monitoring changes in cognition in a subject having or suspected of having dementia is also provided. Corresponding kits, assay devices and uses are also provided.

traducir

METHOD FOR MONITORING POST-TRANSLATIONAL MODIFICATION OF PROTEIN

NºPublicación: US2020088743A1 19/03/2020

Solicitante:

KOREA INST SCI & TECH [KR]

WO_2018143531_A1

Resumen de: US2020088743A1

According to a method for monitoring post-translational modifications of protein is provided, a first microbead by binding a protein antibody to a base bead is provided. A second microbead by binding a target protein having a first post-translational modification or a second post-translational modification, which are inversely proportional to each other, to the protein antibody of the first microbead, is provided. A third microbead by binding the second microbead to a first post-translational modification antibody is provided. A fourth microbead by binding the second microbead to a second post-translational modification antibody is provided. Impedances of the third and fourth microbeads are measured. A ratio of a first difference, between the impedances of the third microbead and a reference impedance, to a second difference, between the impedances of the fourth microbead and the reference impedance, is obtained.

traducir

METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)

NºPublicación: US2020087704A1 19/03/2020

Solicitante:

ST JUDE CHILDRENS RES HOSPITAL [US]

US_2018057854_A1

Resumen de: US2020087704A1

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

traducir

SYSTEMS

NºPublicación: EP3622057A1 18/03/2020

Solicitante:

NEW YORK STEM CELL FOUND INC [US]

US_2020087665_A1

Resumen de: WO2018206798A1

An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.

traducir

Procédé de purification d'une solution.

NºPublicación: CH715311A1 13/03/2020

Solicitante:

FOND LUC MONTAGNIER [CH]

Resumen de: CH715311A1

L’invention concerne un procédé de purification au moins partielle d’une solution, typiquement un plasma sanguin, qui comprend une étape de mise de la solution sous l’influence d’un composé soufré notamment disulfure. Le procédé a pour effet la suppression des séquences aqueuses dérivées de l’ADN de Borrelia burgdorferi par des émanations de gaz H2S. L’invention concerne aussi un procédé de diagnostic d’un état purifié d’une solution contenant initialement un élément biochimique, comprenant les étapes E2 à E6. Un médicament est aussi revendiqué.

traducir

METHOD FOR TREATING BLOOD, BLOOD PRODUCTS AND ORGANS

NºPublicación: JP2020037582A 12/03/2020

Solicitante:

フォルシュングスツェントルムユーリッヒゲゼルシャフトミットベシュレンクテルハフツングForschungszentrumJuelichGmbH

US_2019037835_A1

Resumen de: WO2013150126A2

The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

traducir

IDENTIFICATION OF SIGNATURES FOR NEURODEGENERATION DISEASES DIAGNOSES

NºPublicación: US2020081019A1 12/03/2020

Solicitante:

BIOCROSS S L [ES]

WO_2018166893_A1

Resumen de: US2020081019A1

The present invention is directed to diagnostic methods for differentiating Alzheimer's Disease (AD) patients and Frontotemporal Dementia (FTD) patients versus Healthy Controls. The invention also provides methods for distinguishing between these two neurodegenerative diseases AD and FTD, a method for monitoring the progression of AD and/or FTD, a method for determining the efficacy of an AD and/or FTD therapy and a method for screening compounds to be used against AD and/or FTD.

traducir

Biomarker composition for diagnosing Alzheimer's dementia and use thereof

NºPublicación: KR20200025195A 10/03/2020

Solicitante:

조선대학교산학협력단

Resumen de: KR20200025195A

알츠하이머성 치매 진단용 바이오마커 조성물 및 이의 용도에 관한 것이다. 일 실시예에 따른 조성물, 키트, 및 방법에 의하면, 혈액 샘플을 이용하여 알츠하이머성 치매를 높은 정확도로 조기 진단이 가능하므로, 알츠하이머성 치매 진단 분야의 핵심 기술로 응용될 수 있을 것으로 기대된다.

traducir

METHODS FOR MEASURING CONCENTRATIONS OF BIOMOLECULES IN BIOFLUIDS

NºPublicación: CN110869039A 06/03/2020

Solicitante:

C2N\u8BCA\u65AD\u6709\u9650\u516C\u53F8

AU_2018217478_A1

Resumen de: WO2018148593A1

The present invention provides methods for measuring the absolute concentration of Tau, and other protein, peptide fragments and proteoforms in CSF and plasma samples collected from a subject. Such biomoiecuies may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the CSF or plasma concentration of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

traducir

DETECTION OF MISFOLDED TAU PROTEIN

NºPublicación: CN110869763A 06/03/2020

Solicitante:

安培里翁公司德克萨斯大学系统董事会克劳迪奥·索托贾拉罗素··莱博维兹贝内迪克特··沃尔拉特穆罕默德·沙纳瓦兹尼古拉斯·门德斯·迪纳马卡

KR_20200007945_A

Resumen de: US2018335438A1

Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.

traducir

Peptide biomarker for the diagnosis of Alzheimers Dementia

NºPublicación: KR20200024004A 06/03/2020

Solicitante:

광주과학기술원조선대학교산학협력단전남대학교산학협력단

Resumen de: KR20200024004A

본 발명은 알츠하이머성 치매 환자의 특이적인 자가항체와 결합하는 펩타이드의 알츠하이머성 진단 용도에 관한 것으로, 구체적으로 서열번호 1 내지 5로 구성된 군으로부터 선택된 하나 이상의 아미노산 서열로 이루어진 펩타이드를 유효성분으로 포함하는, 알츠하이머성 치매 진단용 조성물; 진단용 키트; 상기 조성물을 이용한 알츠하이머성 치매 진단을 위한 정보제공방법; 및 서열번호 1 내지 5로 구성된 군으로부터 선택되는 아미노산 서열로 이루어진, 알츠하이머성 치매 환자에서 특이적으로 증가하는 IgM 항체에 결합하는 펩타이드에 관한 것이다. 본 발명에 따른 서열번호 1 내지 5로 구성된 군으로부터 선택된 하나 이상의 아미노산 서열로 이루어지는 펩타이드는 알츠하이머성 치매환자의 혈액 내에서 특이적으로 증가하는 IgM 항체와 특이적으로 결합할 수 있으므로, 혈액을 통한 진단이 불가능하였던 기존 알츠하이머성 치매 진단 방법의 한계점을 극복하고, 혈액을 기반으로 한 알츠하이머성 치매 진단에 이용될 수 있다.

traducir

Peptide biomarker for the diagnosis of Alzheimers Dementia

NºPublicación: KR20200024005A 06/03/2020

Solicitante:

광주과학기술원조선대학교산학협력단전남대학교산학협력단

Resumen de: KR20200024005A

본 발명은 알츠하이머성 치매 환자의 특이적인 자가항체와 결합하는 펩타이드의 알츠하이머성 진단 용도에 관한 것으로, 구체적으로 서열번호 1 내지 5로 구성된 군으로부터 선택된 하나 이상의 아미노산 서열로 이루어진 펩타이드를 유효성분으로 포함하는, 알츠하이머성 치매 진단용 조성물; 진단용 키트; 상기 조성물을 이용한 알츠하이머성 치매 진단을 위한 정보제공방법; 및 서열번호 1 내지 5로 구성된 군으로부터 선택되는 아미노산 서열로 이루어진, 알츠하이머성 치매 환자에서 특이적으로 증가하는 IgG 항체에 결합하는 펩타이드에 관한 것이다. 본 발명에 따른 서열번호 1 내지 5로 구성된 군으로부터 선택된 하나 이상의 아미노산 서열로 이루어지는 펩타이드는 알츠하이머성 치매환자의 혈액 내에서 특이적으로 증가하는 IgG 항체와 특이적으로 결합할 수 있으므로, 혈액을 통한 진단이 불가능하였던 기존 알츠하이머성 치매 진단 방법의 한계점을 극복하고, 혈액을 기반으로 한 알츠하이머성 치매 진단에 이용될 수 있다.

traducir

PEPTIDE BIOMARKER FOR DIAGNOSING ALZHEIMER'S DEMENTIA

NºPublicación: WO2020045962A1 05/03/2020

Solicitante:

GWANGJU INST SCIENCE & TECH [KR]
UNIV NAT CHONNAM IND FOUND [KR]
UNIV CHOSUN IACF [KR]

Resumen de: WO2020045962A1

The present invention pertains to the use of a peptide for Alzheimer's diagnosis, wherein the peptide binds to specific autoantibodies in patients with Alzheimer's dementia. Specifically, the present inventions pertains to: an Alzheimer's dementia-diagnostic composition containing, as an active ingredient, a peptide consisting of one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1-10; a diagnostic kit; a method for providing information for diagnosing Alzheimer's dementia using the composition; and a peptide which consists of amino acid sequences selected from the group consisting of SEQ ID NOs: 1-10 and binds to antibodies that specifically increase in patients with Alzheimer's dementia. Since the peptide according to the present invention can specifically bind to antibodies that specifically increase in the blood of patients with Alzheimer's dementia, the peptide can overcome the limitations of conventional Alzheimer's dementia diagnosis methods which were incapable of diagnosis through blood, and can be used for blood-based Alzheimer's dementia diagnosis.

traducir

HUMANIZED ANTIBODY

NºPublicación: US2020055928A1 20/02/2020

Solicitante:

AC IMMUNE SA [CH]
GENENTECH INC [US]

US_2018327485_A1

Resumen de: US2020055928A1

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.

traducir

CATABODIES AND METHODS OF USE THEREOF

NºPublicación: WO2020037258A1 20/02/2020

Solicitante:

AB STUDIO INC [US]

Resumen de: WO2020037258A1

The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Αβ) peptides and methods of use thereof.

traducir

Protein-based therapy and diagnosis of tau-medicated pathology in Alzheimer's disease

NºPublicación: AU2020200624A1 20/02/2020

Solicitante:

AXON NEUROSCIENCE SE [CY]

CN_109265543_A

Resumen de: AU2020200624A1

H:\nterwoven\NRPortbl\DCC\FMT\19805074 _.docx-29/01/2020 The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

traducir

Methods For The Treatment Of Neurodegeneration

NºPublicación: US2020055921A1 20/02/2020

Solicitante:

MOMENTA PHARMACEUTICALS INC [US]

ES_2708759_T3

Resumen de: US2020055921A1

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

traducir

BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS

NºPublicación: US2020057079A1 20/02/2020

Solicitante:

MCBI INC [JP]

ES_2617918_T3

Resumen de: US2020057079A1

Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

traducir

ANTI-PHF-TAU ANTIBODIES AND USES THEREOF

NºPublicación: CN110799531A 14/02/2020

Solicitante:

詹森生物科技公司

MX_2019010922_A

Resumen de: US2018265575A1

Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

traducir

CYCLIC AMYLOID-BETA-BINDING PEPTIDES AND THE USE THEREOF

Nº publicación: JP2020023510A 13/02/2020

Solicitante:

フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング

US_2018111971_A1

Resumen de: WO2015043566A1

The invention relates to a peptide comprising at least one peptide which binds to an amyloid-beta species. The peptide has an amino acid sequence which is present in cyclized form. The invention also relates to the use of the peptides in the medical field, in particular for the treatment of Alzheimer's disease.

traducir

Página1 de 2 nextPage por página

punteroimgVolver